Safety and Immunogenicity of Bivalent and Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Flavivirus-Naive Adults Aged 18 to 45 Years.
Phase of Trial: Phase II
Latest Information Update: 02 Mar 2015
At a glance
- Drugs CYD TDV (Primary) ; Dengue vaccine; Japanese encephalitis vaccine
- Indications Dengue
- Focus Adverse reactions
- Sponsors sanofi pasteur
- 12 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Mar 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
- 12 Mar 2010 Actual patient number (154) added as reported by ClinicalTrials.gov.